Emerging approaches for histone deacetylase inhibitor drug discovery

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylases (HDACs) are crucial regulators of gene expression implicated in various cancers and non-cancerous diseases.
• Overexpressed HDACs are linked to malignancies, neurological disorders, inflammation, and viral infections.
• HDAC inhibitors (HDACis) are a developing therapeutic strategy, with several compounds in clinical trials.

Purpose of the Study:

• To review recent advancements in HDAC inhibitor drug development.
• To explore the therapeutic potential of HDAC inhibitors in treating cancerous, neurological, inflammatory, and viral diseases.

Main Methods:

• Literature review of recent studies on HDAC inhibitor drug development.
• Analysis of potential therapeutic applications across various disease types.

Main Results:

• Ongoing development of novel, potent, and selective HDAC inhibitors.
• HDAC inhibitors show therapeutic promise for a range of conditions.

Conclusions:

• Continued research is essential for developing more selective HDAC inhibitors to minimize side effects.
• Combination therapies involving HDAC inhibitors and other epigenetic modulators may offer synergistic therapeutic benefits.